Nuclera has appointed Carl Raimond as Chief Executive Officer, effective immediately. Dr Michael Chen, Nuclera’s Co-founder and former CEO, transitions to the role of Chief Scientific and Business Officer, continuing to provide scientific leadership while supporting market development and strategic partnerships. 

The leadership transition reportedly marks the next phase in Nuclera’s evolution as the company builds on more than a decade of expertise in cell-free protein synthesis, digital microfluidics and protein production. The combination of Raimond’s experience scaling life-science businesses with Chen’s scientific leadership and deep understanding of Nuclera’s technology and markets will support the company as it expands adoption of its platform across priority life-science workflows. 

Raimond joins Nuclera from Thermo Fisher Scientific, where he served as President of Proteomic Sciences following its acquisition of Olink Proteomics. He previously served as President of Olink Proteomics, helping lead the company through its $3.1 billion acquisition by Thermo Fisher Scientific in 2023. An experienced life sciences executive, Raimond has also held senior leadership roles at PerkinElmer, Agilent Technologies and Affymetrix. 

As Chief Scientific and Business Officer, Chen will focus on scientific strategy, market development and strategic partnerships, working closely with Raimond as the company enters its next phase of growth whilst maintaining continuity in Nuclera’s scientific direction. 

Raimond said: “Nuclera has built a differentiated technology platform at the intersection of cell-free protein synthesis, digital microfluidics, and protein discovery. I’m excited to join the company as we sharpen our focus on customer adoption, commercial execution, and expanding applications of our technology across life-science workflows.” 

Chen added: “As a structural biologist, I know firsthand the time and frustration protein production can cost a development programme. That frustration is part of why we started Nuclera. I’m incredibly proud of what the team has built and the difference our technology is already making for protein scientists. Now, we’ve reached an important point in the company’s evolution, and Carl is the right CEO to lead us forward.”